ProteoNic
Pre-clinicalProteoNic’s premium vector technology boosts the production of complex proteins such as difficult-to-express multi-specific antibodies and fusion proteins.
Founded
2005
Focus
BiologicsAntibodies
About
ProteoNic’s premium vector technology boosts the production of complex proteins such as difficult-to-express multi-specific antibodies and fusion proteins.
Funding History
2Total raised: $10.5M
Series A$8MUndisclosedJun 15, 2015
Seed$2.5MUndisclosedJun 15, 2012
Company Info
TypePrivate
Founded2005
LocationLeiden, Netherlands
StagePre-clinical
Contact
SIMILAR COMPANIES
2-BBB Medicines
Pre-clinical · Leiden
Batavia Biosciences
Pre-clinical · Leiden
Bilthoven Biologicals
Pre-clinical · Bilthoven
Agendia
Pre-clinical · Amsterdam
Alloksys Life Sciences
Phase 2 · Wageningen
Is this your company?
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile